<DOC>
	<DOCNO>NCT00606502</DOCNO>
	<brief_summary>The purpose clinical study determine effectiveness ( ability provide beneficial treatment disease ) safety pralatrexate compare erlotinib give non-small cell lung cancer ( NSCLC ) patient current former cigarette smoker receive least 1 prior treatment platinum drug ( cisplatin carboplatin )</brief_summary>
	<brief_title>Study Pralatrexate vs. Erlotinib Non-Small Cell Lung Cancer After Least 1 Prior Platinum-based Treatment</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Vitamins</mesh_term>
	<mesh_term>Vitamin B 12</mesh_term>
	<mesh_term>Hydroxocobalamin</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>10-deazaaminopterin</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<mesh_term>Aminopterin</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Confirmed Stage IIIB/ IV nonsmall cell lung cancer ( NSCLC ) . Relapsed treatment 1 2 prior chemotherapy regimen , include least 1 platinumbased treatment . Patients may receive pemetrexed 1 prior therapy . Patients may receive investigational therapy prior therapy . Recovered toxic effect prior therapy . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 . Smoked ≥ 100 cigarette lifetime , whether former current cigarette smoker . Adequate blood , liver kidney function define laboratory value . Received 11.25 mg daily oral folic acid least 7 day prior randomization 1 mg intramuscular injection vitamin B12 within 10 week prior randomization . Women childbearing potential must use medically acceptable birth control negative serum pregnancy test within 14 day prior randomization . Patients postmenopausal least 1 year ( &gt; 12 month since last menses ) surgically sterilize require test . Men surgically sterile must use medically safe effective birth control time study randomization , agree continue practice least 90 day last administration study treatment . Accessible repeat dose followup . Give write informed consent . Active concurrent primary malignancy ( except nonmelanoma skin cancer situ carcinoma cervix ) . If history prior malignancy , patient must diseasefree ≥ 5 year . Patients prior malignancy less 5 year study entry may still enrol receive treatment result complete resolution cancer currently evidence active recurrent disease . Use investigational drug , biologics , device within 4 week prior randomization . Previous exposure pralatrexate erlotinib . Women pregnant breastfeeding . Congestive Heart Failure Class III/IV accord New York Heart Association ( NYHA ) Functional Classification . Uncontrolled hypertension . Human immunodeficiency virus ( HIV ) positive diagnosis CD4 count &lt; 100 mm3 detectable viral load within past 3 month , receive combination antiretroviral therapy . Symptomatic central nervous system metastases lesion treatment require . Major surgery within 2 week study randomization . Receipt conventional systemic chemotherapy within 4 week ( 6 week nitrosoureas , mitomycin C ) , radiation therapy ( RT ) within 2 week , prior randomization . Active infection serious underlie medical condition , would impair ability patient receive protocol treatment . Dementia significantly alter mental status would prohibit understanding give informed consent limit study compliance .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Stage IIIB/IV non-small cell lung cancer</keyword>
	<keyword>Non-small cell lung cancer</keyword>
	<keyword>NSCLC</keyword>
	<keyword>Lung Cancer</keyword>
	<keyword>Pralatrexate</keyword>
	<keyword>Erlotinib</keyword>
	<keyword>Tarceva</keyword>
	<keyword>PDX</keyword>
	<keyword>Smoking</keyword>
	<keyword>Smoker</keyword>
</DOC>